Brentuximab Vedotin and Bendamustine Proves Effective as Second-line Hodgkin Lymphoma Treatment

Share this content:
Coupled with ASCT, a Brentuximab vedotin–bendamustine combination therapy may improve outcomes in patients.
Coupled with ASCT, a Brentuximab vedotin–bendamustine combination therapy may improve outcomes in patients.

Brentuximab vedotin plus bendamustine may be an effective and safe salvage therapy among patients with relapsed/refractory Hodgkin lymphoma (RR HL) compared with platinum-based chemotherapy prior to autologous stem cell transplant (ASCT), according to a study published in The Lancet Oncology.1

Previous studies demonstrated that brentuximab vedotin and bendamustine monotherapies improve the overall response rate (ORR) of patients with RR HL, though no meaningful progression-free survival (PFS) improvement was noted.

For this 2-part phase 1/2 study ( Identifier: NCT01657331), investigators enrolled 65 patients (98% of whom had Hodgkin lymphoma; 28 patients during stage 1 and 37 during stage 2) who had failed at least 1 previous chemotherapy regimen. Stage 1 of the study was an exploratory dose-determining study; in stage 2, patients received the recommended dose from stage 1.

A maximum tolerated dose was not reached for phase 1, but dose-limiting neutropenia and diffuse rash were observed in 2 patients and 1 patient, respectively.

Patients who received the recommended phase 1 dose of brentuximab vedotin 1.8 mg/kg plus bendamustine 90 mg/m2 had an overall response of 78% (95% CI, 62%-91%).

The most frequently reported serious adverse events included grade 3 lung infection and grade 3 or 4 neutropenia. No treatment-related deaths were reported.

The authors of the study concluded that brentuximab vedotin plus bendamustine has potential as a treatment in the setting and thereafter. They concluded that “coupled with ASCT, this combination therapy might achieve a substantial improvement in these patients compared with traditional, platinum-based salvage regimens. Further studies, preferably randomized trials that will allow formal cross-regimen efficacy comparisons, are warranted.”


1. O'Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2017 Dec 21. doi: 10.1016/S147-(17)30912-9 [Epub online ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs